N/A N=62 Effects of Micronutrient (Chromium) Supplementation on Diabetes
Diabetes Mellitus, Type 1
Primary: Blood Glucose Level — 172.39; 212.85; 164.47; 191.25 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=309 Examination of the Effects of Chromium Levels on Glucose Metabolism, Lipid Metabolism, Morbidity and Mortality Rates in Patients Followed in Intensive Care Unit
Chromium Deficiency · Diabetes Mellitus · Hyperlipidemias
Primary: Serum Chromium Level — 8.93; 9.74; 9.68; 11.01 µg/L
N/A N=50 Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis
Allergic Contact Dermatitis
Primary: Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0) — 14.53; 16.03; 109.1; 110.7 pg/ml
N/A N=101 Choline Nutritional Status: Development of a Biomarker Panel
Healthy
Primary: Ratio of Liver Choline Pool Size by Isotope Dilution — 0.02357; 0.02403; 0.02184; 0.00023 isotopic enrichment ratio — p=0.0247
Phase 4 N=60 A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh
Arsenic Metabolites Measured in Urine
Primary: Change in Urinary % Monomethyl Arsenic — 2.4; 0.24; -0.06; -3.2 percentage of total urinary arsenic
Phase 3 N=199 Weekly Zinc Chelate Supplementation on Children's Growth
Short Stature
Primary: Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period. — 0.04; -0.08; 0.10; 0.02 Z-Score — p=<0.05
N/A N=13 90-Day Cobalt Supplementation Study to Investigate the Cobalt Body Burden in Ten Healthy Adult Volunteers
Cobalt Biokinetics · Safety of Cobalt Dietary Supplementation
Primary: Cobalt Whole Blood Concentrations — 14.6; 7.4; 33.9; 8.5 µg Co/L
N/A N=10 Choline and Cardiometabolic Health
Cardiovascular Risk Factor
Primary: Change From Baseline in Insulin Sensitivity at 4 Weeks — 0.28; -0.29 Calculated Ratio - No units
Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05
N/A N=28 Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes
Diabetes Type 2
Primary: Diff AUC SS0.5 Hyperglycemic — 0.74; 0.96 Pa*hr
N/A N=206 Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans
Thiamine Deficiency · Thiamine Deficiency; Sequelae
Primary: Percentage of Participants With Thiamine Deficiency (Low Plasma Thiamine) Out of Total Number of Enrolled Veterans With Plasma Thiamine Results — 49 Participants
Phase 2 N=29 The Effects of Potassium on Glucose Metabolism in African Americans
Borderline Hypokalemia
Primary: Change in Glucose Tolerance as Measured by Area-under-the-curve — 328; 1000 AUC - mg*min/dL — p=0.5582
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
Phase 3 N=265 Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina
Vitamin D Deficiency · Pregnancy
Primary: 25-hydroxyvitamin D at Visit 7 — 36.7; 39.8 ng/mL
N/A N=809 Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Anemia · Iron Deficiency · Hemoglobin Disorder
Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05
N/A N=16 Oral Iron for Erythropoietic Protoporphyrias
Erythropoietic Protoporphyria · EPP · X-linked Protoporphyria
Primary: Change in Erythrocyte Protoporphyrin Levels — 2314.6; 2240.4 µg/dL
Phase 4 N=1,000 Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes
Anemia · Diarrhea · Iron
Primary: Incidence of Diarrhea — 201; 204; 260; 224 episodes
Phase 3 N=40 Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
Anemia · Renal Failure
Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L
Phase 2 N=60 Copper Histidine Therapy for Menkes Diseases
Kinky Hair Syndrome
Primary: Gross Motor Development at 36 Mos of Age or at Death (Mos) — 13.743; 2.455; 15.667 Other - months
Phase 1 N=19 Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Obesity · Endothelial Dysfunction · Vitamin D Deficiency
Primary: Flow Mediated Dilatation (FMD) — 9.5; 10.4 percentage increase in BAD — p=0.59
N/A N=39 Effect of Cocoa Supplementation Peripheral and Autonomic Diabetic Neuropathy
Diabetic Neuropathies
Primary: Toronto Clinical Scoring System (TCSS) — -2.63; -1.84; 9.31; 6.89 Score on a scale — p=>0.05
Phase 2 N=12 Intravenous Iron Metabolism in Restless Legs Syndrome
Restless Legs
Primary: Duration Off Treatment — 6; 3; 2; 0 participants
N/A N=133 Selenium and Immune Function
Healthy
Primary: Cellular and Humoral Immune Response — 0.29; 0.34; 0.34; 0.29 umol/min — p=<0.05
N/A N=250 Ancillary Study of Methylation Biomarkers in a Randomized Controlled Trial of a Personalized Prevention of Colorectal Cancer
Colorectal Cancer
Primary: Changes of Cytosine Modification in TMPRSS2 (5-mC at cg16371860) by Magnesium Treatment Versus Placebo — 0.007; -0.001; 0.012; -0.002 units on CpG sites — p=<0.05
N/A N=99 hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects
Healthy Subjects · Vitamin D Deficiency
Primary: hCAP18 Levels — 762; 639 ng/ml
N/A N=19 Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery
Vitamin D Deficiency · Gastrointestinal Diseases
Primary: # of Pts w/ Enhanced Vitamin D Status — 3; 3 Participants
N/A N=47 Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Weight Percentile at 3 Months — 33.5; 31.0 Weight Percentile, sex and age adjusted
Phase 2 N=12 Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy
Melanoma
Primary: Overall Response Rate to Treatment of Melanoma With Disulfiram and Chelated Zinc — 0 participants
Phase 4 N=88 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23